Loading...
Found 11 results for lauren-perrey-moore
A listing of lauren-perrey-moore medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Development of trial-ready cohort to facilitate rapid enrollment into Alzheimer’s trials for participants with Down Syndrome (Trial Ready Cohort—Down Syndrome (TRC-DS)
J
Jill Fostad
Who is Eligible Ages 35-55 Must be willing to complete PET scan What is Involved Onsite visits at the IUH Neuroscience Center Visits at the IUH Neuroscience Center every 16 months Compensation Compensation available via payment card for each completed appointment
Alnylam ALN-APP-001: Phase I, placebo-controlled trial of ALN-APP in participants with Early-Onset Alzheimer’s disease
J
Jared Brosch, MD
Who is Eligible Ages 18+ Must have had symptoms of Alzheimer’s disease prior to age 65 Diagnosis of Alzheimer’s disease Must be able to complete MRI Must be able to tolerate lumbar puncture No history of seizures, stroke or cancer in the last 5 years What is Involved In-person visits …
Nicotinic Acid for the treatment of Alzheimer's Disease Protocol Type: Interventional
J
Jared Brosch, MD
The primary objective of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid. One dose of 500 mg nicotinic acid will be used (in addition to placebo) to build a dose response curve for this compound in human cerebrospinal …
Handheld Point Of Care Electro-Diagnostic Device
S
Sergiu Abramovici
We are developing a point of care, hand-held device, to be used by healthcare providers and assist them with clinical decision making and facilitate as well as expedite patient care, thus improving quality of care. The device we are studying is non-invasive, and we think it will improve quality of …
Dominantly Inherited Alzheimer Network (DIAN)
M
Martin Farlow, MD
Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. The overall purpose of this research is to understand the …
A Randomized Controlled, Open-Label, Rater-Blinded Pragmatic Trial, Treatment of Inflammatory Myelitis and Optic Neuritis With Early Vs Rescue Plasma Exchange (Timely-Plex)
D
Devon Mackay
The purpose of this research is to evaluate if early vs rescue Therapeutic Plasma Exchange (PLEX) treatment algorithm leads to better visual outcomes in severe Optic Neuritis and leads to better neurological disability outcomes in severe Transverse Myelitis.THIS STUDY IS ENROLLING BY INVITATION ONLY
Phase Ib Trial of Abbv-637 or Abbv-155 in Combination With Eras-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
K
Kathryn Nevel
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, …
Kysa-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of Kyv-101, an Autologous Fully Human Anti-Cd19 Chimeric Antigen Receptor T-Cell (Cd19 Car T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
A
Alex Barboi
Myasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular junction and is characterized by muscle weakness. B cells play a role in MG, and the disease is characterized by the presence of autoantibodies such as anti-AChR and anti-MuSK antibodies. CD-19 target chimeric antigen receptor (CAR) T cells …
Enroll-HD: Registry trial for participants with Huntington’s disease
C
Christopher James
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD …
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
C
Christopher James
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.THIS STUDY IS ENROLLING BY INVITATION ONLY
Please choose between Voice or SMS based delivery of verification code
or